Hemab Therapeutics Holdings (COAG) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Hemab Therapeutics Holdings (COAG) is Moderate Underperform.

The composite score behind that read is -0.39, weighing +0.00 of bullish evidence against -0.38 bearish.

Hemab Therapeutics Holdings last closed at $30.59, -1.67% on the session.

Against the IVW growth benchmark the position is -2.59% over the forecast window.

The read is built from 11 underlying insights — 0 bullish and 11 bearish.

Agreement across those insights is 100%.

16 graded predictions for COAG so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

Hemab Therapeutics Holdings is classified under Health Care / Biotechnology, with a market capitalisation of $1.45B.

StockMap tracks Hemab Therapeutics Holdings as the 108th largest of the 344 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 180 Moderate Underperform, 152 Neutral, 11 Strong Underperform and 1 Moderate Outperform.

On that composite Hemab Therapeutics Holdings ranks 300th of 344 in the group, against a group median of -0.21.